Clinical Trials Logo

Clinical Trial Summary

Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Lesion progression is driven by abnormal angiogenesis, chronic inflammation, and uncontrolled cell proliferation. KS remains one of the most commonly diagnosed cancers in many African countries where economic constraints prevent successful treatment in most patients. Treatment outcomes in developed countries are also often unsatisfactory in HIV positive patients despite good virological and immunological responses to antiretroviral therapy. Therefore, identification of new oral, safe treatment options for treatment of KS remains a research priority. Given the known anti-angiogenic properties and based on the treatment response with other benign vascular lesions such as infantile hemangioma, propranolol is a good candidate for the treatment of KS. The hypothesis of this study is that treating patients with Kaposi sarcoma with propranolol will result in an overall response rate (complete response rate plus partial response rate) of at least 45%, and that propranolol will be safe and well tolerated in this patient population.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06445166
Study type Interventional
Source Washington University School of Medicine
Contact Lee Ratner, M.D., Ph.D.
Phone 314-362-8836
Email lratner@wustl.edu
Status Not yet recruiting
Phase Phase 2
Start date September 30, 2024
Completion date September 30, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT04941274 - Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma Phase 1/Phase 2
Completed NCT03160183 - Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
Recruiting NCT03993106 - A Study of sEphB4-HSA in Kaposi Sarcoma Phase 2
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Completed NCT00395278 - Development of Serologic Assays for Human Herpes Virus-8
Recruiting NCT02408861 - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Completed NCT03296553 - Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. Phase 2
Recruiting NCT04305691 - Trial of Ixazomib for Kaposi Sarcoma Phase 2
Completed NCT03316274 - Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma Early Phase 1
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Terminated NCT04893018 - NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Phase 1
Recruiting NCT06375122 - Natural History Study of Kaposi Sarcoma
Recruiting NCT05663502 - Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Recruiting NCT05329792 - L19IL2/L19TNF in Skin Cancer Patients Phase 2
Not yet recruiting NCT05411237 - Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma Phase 3
Completed NCT03050788 - Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma N/A
Completed NCT03404297 - Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya N/A
Terminated NCT01412515 - A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma Phase 2
Not yet recruiting NCT06004011 - AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) N/A
Withdrawn NCT02229981 - Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma Phase 1/Phase 2